Mild renal impairment and the efficacy and safety of liraglutide.

Davidson JA, Brett J, Falahati A, Scott D

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 May 2011Cited by 55 (Europe PMC)

PMID21700561DOI10.4158/ep10215.raPepBankPUB-21700561

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes, mild renal impairment did not change the estimated treatment differences in HbA1c with liraglutide.
In plain wordsIn people with type 2 diabetes, mild kidney impairment did not change how well liraglutide lowered HbA1c.
Peptide
Liraglutide
Outcome
No significant changeHbA1c treatment difference by renal function
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Mild RI did not affect the estimated treatment differences in hemoglobin A1c.
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056101
02HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes and normal renal function, liraglutide decreased body weight.
In plain wordsIn people with type 2 diabetes and normal kidney function, liraglutide lowered body weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight change, normal renal function
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Patients with normal renal function demonstrated decreases in body weight and systolic blood pressure with either dosage of liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056102
03HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes and normal renal function, liraglutide decreased systolic blood pressure.
In plain wordsIn people with type 2 diabetes and normal kidney function, liraglutide lowered systolic blood pressure.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change, normal renal function
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Patients with normal renal function demonstrated decreases in body weight and systolic blood pressure with either dosage of liraglutide
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056103
04HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes and renal impairment, the decrease in body weight with liraglutide was not significant compared with placebo.
In plain wordsIn people with type 2 diabetes and kidney impairment, weight loss with liraglutide was not significantly different from placebo.
Peptide
Liraglutide
Outcome
No significant changeBody weight change, renal impairment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
whereas patients in either RI group also demonstrated a decrease in body weight and systolic blood pressure, but these differences were not significant compared with differences observed in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056104
05HumanSystematic reviewEfficacy outcome
In patients with type 2 diabetes and renal impairment, the decrease in systolic blood pressure with liraglutide was not significant compared with placebo.
In plain wordsIn people with type 2 diabetes and kidney impairment, the drop in blood pressure with liraglutide was not significantly different from placebo.
Peptide
Liraglutide
Outcome
No significant changeSystolic blood pressure change, renal impairment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
whereas patients in either RI group also demonstrated a decrease in body weight and systolic blood pressure, but these differences were not significant compared with differences observed in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056105
06HumanSystematic reviewSafety outcome
In patients with type 2 diabetes and mild renal impairment, liraglutide did not differ from placebo in the rate of renal injury.
In plain wordsIn people with type 2 diabetes and mild kidney impairment, liraglutide caused no more kidney injury than placebo.
Peptide
Liraglutide
Outcome
No significant changeRenal injury in mild renal impairment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide treatment vs placebo was safe and well tolerated in patients with mild RI, as there were no significant differences in rates of renal injury, minor hypoglycemia, or nausea.
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056106
07HumanSystematic reviewSafety outcome
In patients with type 2 diabetes and mild renal impairment, liraglutide did not differ from placebo in the rate of minor hypoglycemia.
In plain wordsIn people with type 2 diabetes and mild kidney impairment, liraglutide caused no more mild low blood sugar than placebo.
Peptide
Liraglutide
Outcome
No significant changeMinor hypoglycemia in mild renal impairment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide treatment vs placebo was safe and well tolerated in patients with mild RI, as there were no significant differences in rates of renal injury, minor hypoglycemia, or nausea.
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056107
08HumanSystematic reviewSafety outcome
In patients with type 2 diabetes and mild renal impairment, liraglutide did not differ from placebo in the rate of nausea.
In plain wordsIn people with type 2 diabetes and mild kidney impairment, liraglutide caused no more nausea than placebo.
Peptide
Liraglutide
Outcome
No significant changeNausea in mild renal impairment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide treatment vs placebo was safe and well tolerated in patients with mild RI, as there were no significant differences in rates of renal injury, minor hypoglycemia, or nausea.
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056108
09HumanSystematic reviewSafety outcome
In patients with type 2 diabetes and moderate or severe renal impairment, a trend toward more nausea with liraglutide was seen, but the group was too small to determine significance.
In plain wordsWith moderate or severe kidney impairment and type 2 diabetes, nausea tended to be higher with liraglutide; the group was too small to tell.
Peptide
Liraglutide
Outcome
No significant changeNausea in moderate or severe renal impairment
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
A trend towards increased nausea was observed in patients with moderate or severe RI receiving liraglutide, although the number of patients in this treatment group was too low to determine significance.
2 context sentences(design, population, supporting numbers)
Summary · context
In this meta-analysis, we examined the 6 LEAD (Liraglutide Effect and Action in Diabetes) studies.
Summary · context
The meta-analysis included patients administered once-daily liraglutide (1.2 or 1.8 mg) or placebo as either monotherapy or in combination with oral antidiabetic drugs for 26 weeks.
Report a problemFND-2170056109

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.